Jefferies Financial Group Inc. Sells 1,483,073 Shares of Indivior PLC $INDV

Jefferies Financial Group Inc. decreased its position in Indivior PLC (NASDAQ:INDV) by 67.7% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 707,201 shares of the company’s stock after selling 1,483,073 shares during the period. Jefferies Financial Group Inc.’s holdings in Indivior were worth $17,051,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. SPX Gestao de Recursos Ltda purchased a new position in shares of Indivior in the 3rd quarter worth approximately $675,000. Barclays PLC increased its position in shares of Indivior by 1.2% during the third quarter. Barclays PLC now owns 2,124,553 shares of the company’s stock valued at $51,223,000 after acquiring an additional 25,493 shares during the last quarter. Dimensional Fund Advisors LP bought a new stake in Indivior during the third quarter worth $14,531,000. Victory Capital Management Inc. bought a new stake in Indivior during the third quarter worth $19,437,000. Finally, Royce & Associates LP purchased a new position in Indivior in the third quarter worth $5,944,000. Institutional investors own 60.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on INDV shares. HC Wainwright upped their price objective on Indivior from $35.00 to $48.00 and gave the company a “buy” rating in a research note on Monday, January 12th. Weiss Ratings upgraded Indivior from a “hold (c)” rating to a “buy (b-)” rating in a research note on Monday, March 2nd. Northland Securities set a $50.00 price target on shares of Indivior in a research report on Tuesday, January 20th. Zacks Research downgraded shares of Indivior from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 13th. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $36.00 price objective on shares of Indivior in a research report on Wednesday, December 3rd. Six analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, Indivior presently has a consensus rating of “Moderate Buy” and a consensus target price of $39.33.

Insider Buying and Selling at Indivior

In other Indivior news, Director David E. Wheadon bought 1,771 shares of Indivior stock in a transaction dated Monday, January 5th. The stock was purchased at an average price of $35.39 per share, for a total transaction of $62,675.69. Following the completion of the purchase, the director directly owned 14,395 shares of the company’s stock, valued at approximately $509,439.05. This trade represents a 14.03% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Keith Humphreys bought 775 shares of Indivior stock in a transaction dated Monday, January 5th. The stock was acquired at an average price of $35.39 per share, with a total value of $27,427.25. Following the purchase, the director directly owned 5,802 shares of the company’s stock, valued at approximately $205,332.78. This represents a 15.42% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders bought 4,871 shares of company stock valued at $172,385.

Indivior Price Performance

Shares of INDV opened at $32.27 on Monday. Indivior PLC has a 1 year low of $8.64 and a 1 year high of $38.00. The stock’s fifty day moving average price is $34.11 and its two-hundred day moving average price is $30.39. The firm has a market cap of $4.04 billion, a PE ratio of 19.68 and a beta of 0.83.

Indivior (NASDAQ:INDV) last posted its quarterly earnings results on Thursday, February 26th. The company reported $0.82 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.17. Indivior had a negative return on equity of 148.76% and a net margin of 16.85%.The company had revenue of $358.00 million during the quarter, compared to the consensus estimate of $305.62 million. Sell-side analysts anticipate that Indivior PLC will post 1.22 earnings per share for the current fiscal year.

Indivior Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.